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Abstract 
Background: The diagnostic accuracy of diffusion-weighted imaging (DWI) to detect 
prostate cancer is well-established.  DWI provides visual and also quantitative means of 
detecting tumor, the Apparent Diffusion Coefficient (ADC). Recently higher b-values 
have been used to improve DWI’s diagnostic performance. 
Purpose: To determine the diagnostic performance of high b-value DWI at detecting 
prostate cancer and whether quantifying ADC improves accuracy. 
Material and Methods: A comprehensive literature search of published and unpublished 
databases was performed. Eligible studies had histopathologically proven prostate cancer, 
DWI sequences using b-values ≥ 1000 s/mm2, > 10 patients, and data for creating a 2x2 
table. Study quality was assessed with QUADAS-2 (Quality Assessment of diagnostic 
Accuracy Studies). Sensitivity and specificity were calculated and tests for statistical 
heterogeneity and threshold effect performed. Results were plotted on a summary 
receiver operating characteristic curve (sROC) and the area under the curve (AUC) 
determined the diagnostic performance of high b-value DWI. 
Results: Ten studies met eligibility criteria with 13 subsets of data available for analysis, 
including 522 patients. Pooled sensitivity and specificity were 0.59 (95% CI 0.57–0.61) 
and 0.92 (95% CI 0.91–0.92) respectively and the sROC AUC was 0.92. Subgroup 
analysis showed a statistically significant (p=0.03) improvement in accuracy when using 
tumor visual assessment rather than ADC. 
Conclusion: High b-value DWI gives good diagnostic performance for prostate cancer 
detection and visual assessment of tumor diffusion is significantly more accurate than 
ROI measurements of ADC. 
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Introduction 
 
Prostate cancer is the most commonly diagnosed cancer, and second-most-common cause 
of cancer-related death in men (1,2). Magnetic resonance imaging (MRI) is the imaging 
mainstay of prostate cancer localization, being recommended in men considered for 
radical treatment following positive trans-rectal ultrasound (TRUS) biopsy, and in high 
risk patients with a negative biopsy, active surveillance, response to treatment, and 
recurrence (3,4).  
Multi-parametric MRI of the prostate comprises T1-weighted and T2-weighted imaging, 
with additional techniques such as diffusion-weighted imaging (DWI) and dynamic 
contrast-enhanced MRI (3). DWI has become a routine part of prostate MRI protocols, 
as it provides good tumor contrast without exogenous agents. 
Applying DWI with multiple diffusion weightings, or b-values, allows the apparent 
diffusion coefficient (ADC) to be estimated: a parameter known to inversely correlate 
with tumor aggressiveness (5,6). Clinically, both diffusion-weighted images, typically 
higher b-values, and ADC maps are assessed to detect tumor, which  appears bright on 
diffusion images and dark on ADC maps.  
ADC maps are calculated through monoexponential fits to diffusion signal decays on 
a voxel-by-voxel basis. Other signal models, have been applied to prostate DWI, 
including diffusional kurtosis (7), intravoxel incoherent motion (8) the stretched 
exponential (9), and VERDICT (10). However, the monoexponential model is the most 
common, requiring only two b-values for fitting.  
Performing monoexponential fitting with higher maximum b-values, bmax, can 
improve contrast-to-noise in the resulting maps, where contrast-to-noise is defined as: 
(Signal(lesion) – Signal (background))/estimated noise [R1 M2].  This gives better 
characterization of ADC differences between normal and cancerous prostate, improving 
tumor detection at the expense of reduced signal-to-noise and increased sensitivity to 
motion artifacts. At 1.5T, bmax of 500 and 1000 s/mm
2 are typically used, but increased 
signal-to-noise at higher field strengths permits the use of higher bmax (11). Guidelines 
recommend a bmax of 800–1000 s/mm2 (3); but there is no consensus on whether higher 
b-values (bmax  ≥ 1000 s/mm2) should be used routinely. Many studies have compared 
high and lower b-value (bmax < 1000 s/mm2) acquisitions, but results have been 
conflicting (12–17).   
 
The diagnostic accuracy of DWI is well-established, with multiple meta-analyses 
reporting its diagnostic performance (18–20). There is uncertainty about the usefulness 
of high b-value DWI, particularly which b-value provides ADC maps with the greatest 
diagnostic performance. The aim of this study is to determine the diagnostic performance 
of high b-value DWI at detecting prostate cancer and whether quantifying ADC improves 
accuracy.  
 
 
Material and Methods 
 
This meta-analysis was reported using the preferred reporting items for systematic 
reviews and meta-analyses outlined in the PRISMA statement (21). The review was 
registered prior to commencing on PROSPERO (Ref No: CRD42015027644). 
 
Search strategy 
A comprehensive systematic literature search was independently performed by two 
reviewers (KCG, TSy) to identify studies investigating the diagnostic accuracy or 
performance of high b-value DWI for detecting prostate cancer. A MEDLINE search is 
presented in Supplementary Table 1.  In addition, searches were conducted of EMBASE, 
and the grey literature/trial registry databases: WHO International Clinical Trials Registry 
Platform and OpenGrey. Studies were not limited by country of origin, but were limited 
to those published in English. All searches were from database inception to 1st January 
2016.   
 Eligibility criteria 
Retrospective and prospective studies were included if they reported detection of prostate 
cancer in a pre-treatment population using high b-value DWI of the prostate. Only 
primary research articles, available as full-text, were accepted; however, review articles 
were checked for additional primary references. High b-value was defined as bmax ≥ 1000 
s/mm2. Histopathological results as a reference standard (biopsy or radical 
prostatectomy), sufficient data to calculate true positive (TP), false positive (FP), false 
negative (FN), and true negative (TN) data were required. If multiple b-values were used, 
including b < 1000 s/mm2, the study was only eligible if data with b ≥ 1000 s/mm2 could 
be extracted. Studies using high b-value DWI in combination with other diagnostic 
sequences to detect cancer were excluded. 
 
Study identification 
Titles and abstracts from the search results, and the full-text papers for all studies which 
met or potentially met the eligibility criteria, were independently reviewed by two 
reviewers (KCG, TSy). Those studies which met the eligibility criteria on full review 
were included in the final analysis. Disagreements on inclusion suitability were resolved 
by consensus (KCG, TSy). 
 
Data extraction 
Two reviewers (KCG, TSy) independently extracted the data on a pre-defined template, 
including: publication year, country of origin, sample size, description of study 
population (age), study design (prospective, retrospective, or unknown), patient 
enrollment (consecutive or not), inclusion and exclusion criteria, reasons for exclusions 
from analysis, and number of experts who assessed and interpreted MRI results. Data 
were recorded on: blinding of MRI measurements to clinical, biochemical or 
histopathological results; methods used to determine diagnosis; types of coils; and b-
values used. For each study, we recorded the number of true-positive, false-positive, true-
negative, and false-negative findings for high b-value DWI in diagnosing prostate cancer. 
Disagreements in data extraction findings were resolved through discussion or through 
adjudication with a third reviewer (TSm). 
 
Quality Assessment 
Two reviewers (KCG, TSy) independently assessed each included paper’s quality using 
QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) (22). Any 
disagreements were resolved through discussion or through adjudication with a third 
reviewer (TSm). 
 
Statistical analysis 
Study heterogeneity was assessed through examination of the data extract table. This 
indicated broad study homogeneity, meaning a meta-analysis was appropriate. Statistical 
heterogeneity was assessed using the chi-squared statistic, Q, and the inconsistency, 𝐼2. 
When p < 0.10 and 𝐼2  > 50%, unexplained statistical heterogeneity was evident and 
diagnostic performance analyses were performed using a random-effects model. 
Specificity and sensitivity of each study was calculated using 2 × 2 contingency tables. 
Pooled sensitivity and specificity and positive and negative likelihood ratios with 95% 
CIs were calculated. Finally, the specificity and sensitivity were used to calculate a 
summary receiver operating characteristic (sROC) curve and the area under the curve 
(AUC). 
The threshold effect was assessed visually, by determining whether the sROC curve 
presented with a ‘shoulder-arm’ shape, and qualitatively using the Spearman correlation 
coefficient of the logit of sensitivity and the logit of (1-specificity), with p <0.05 
indicating the heterogeneity between studies could not be explained by threshold effect. 
A meta-regression and subgroup analysis was performed to explore other sources of 
heterogeneity and how they influence diagnostic performance. 
 
All statistical computations were performed using Meta-DiSc (version 1.4, Javier 
Zamora) and Review Manager (version 5.3. Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2014). 
 
Results 
Search results 
 
A summary of the search strategy results is presented in Supplementary Fig. 1. In total, 
351 studies were identified from the search results, of which 61 were deemed potentially 
eligible. After full-text review, 10 studies met the final eligibility criteria and were 
included in the analysis  (16,17,23–30). 
 
Characteristics of included studies 
The principle characteristics of the included studies are displayed in Table 1, with 
imaging and study methods listed in Table 2. From the 10 included studies, 522 patients 
were analyzed, with mean (range) age = 64 (43–87) years. The mean and median prostate-
specific antigen was 19 and 9.3 ng/mL, respectively.  
 
Three studies were prospective and seven retrospective. Field strengths of 1.5T 
(23,25,26,28,29) and 3T (16,17,24,27,30) were each used in five studies. Radical 
prostatectomy specimens were used as the reference standard in six studies 
(16,17,25,27,29,30), biopsy specimens in three (23,24,26) and one study used a 
combination (28). The MRI reader was blinded in eight studies (16,17,23,25–28,30), 
blinding was not known in two. Anti-spasmodic agents, either glucagon or hyoscine 
butylbromide, were used in five studies (16,17,24,29,30) and their use unknown in the 
remainder. Five studies (16,17,24,29,30) used b-values > 1000 s/mm2.  
 
Several methods were used to detect prostate cancer: region-of-interest (ROI) based  ADC 
quantification was used in six studies (23,24,26–29); and visual assessment of lesions 
using ADC maps was performed in four studies (16,17,25,30), of which two (17,30) used 
a scale (such as Likert scale), and the other two used a binary cut-off.  
 
All ten studies used the monoexponential function only to estimate ADC. In 3 studies 
(16,17,27), extracted data were split into subsets. Kim et al. (16) and Koo et al. (17) 
generated multiple ADC maps: b = (0, 1000), and (0, 2000) s/mm2 for the former, and b 
= (0, 300), (0, 700), (0, 1000),  and (0, 2000) s/mm2 for the latter. Rosenkrantz et al. (27) 
split results from the peripheral zone and the transitional zone. The other studies 
generated only one set of ADC maps from their DWI data, performing monoexponential 
fitting to all acquired b-values. 
 
Quality assessment 
 
Study quality assessment is presented in Supplementary Table 2. Fig. 2 demonstrates the 
QUADAS-2 graphical summary of the studies indicating the proportion of high, low, or 
unclear risk in each domain. A high risk of bias was demonstrated in the patient selection 
domain, but overall the quality of the studies included was considered ‘good’. 
 
Diagnostic performance 
Diagnostic results of the meta-analyses are presented in Table 3. The results from the 
individual studies are presented in Supplementary Table 3. 
The pooled sensitivity and specificity of high b-value DWI MRI in detecting prostate 
cancer were 0.59 (95% CI: 0.57–0.61; Fig. 2) and 0.92 (95% CI: 0.91–0.92; Fig. 3), 
respectively. Sensitivity and specificity heterogeneity tests gave Q = 435.05 (p ≪ 0.001), 
𝐼2  = 97.2% and Q = 89 (p ≪ 0.001), 𝐼2   = 86.5% respectively, indicating significant 
statistical heterogeneity between studies. 
The pooled positive and negative likelihood ratios for high b-value DWI MRI in detecting 
prostate cancer were 6.64 (95% CI: 4.9–9.0; Supplementary Fig. 2) and 0.33 (95% CI: 
0.2–0.5; Supplementary Fig. 3), respectively. Positive and negative likelihood ratio 
heterogeneity tests gave Q = 82.50 (p ≪ 0.001), 𝐼2  = 85.5% and Q = 517.45 (p ≪ 0.001), 
𝐼2  = 97.7%, respectively, indicating significant statistical heterogeneity between studies. 
 
Fig. 4 shows the sROC curve of the 10 studies, where AUC = 0.92, indicating ‘good’ 
diagnostic accuracy (31). 
 
Meta-regression analysis 
The ROC curve did not demonstrate a ‘shoulder-arm’ shape (Supplementary Table 4) and 
the Spearman Correlation Coefficient between the logit of sensitivity and the logit of (1-
specificity) was 0.286 (p=0.344), confirming that the threshold effect is not responsible 
for the variation in accuracy between studies.  
 
Subgroup analysis 
Subgroup analysis was based on different study characteristics and perceived sources of 
bias and applicability uncovered in the QUADAS assessment. Studies at 3T with and 
without an endorectal coil demonstrated the highest pooled sensitivity of 0.76 (95% CI: 
0.71–0.80) and 0.74 (95% CI: 0.71–0.79) respectively. When assessing protocols with a 
bmax > 1000 s/mm
2, the pooled specificity and AUC of the sROC were greater: 0.94 (95% 
CI: 0.93–0.95) and 0.98, respectively. A statistically significant (p<0.05) improvement 
was seen using assessment of tumor presence on ADC maps as a visual threshold versus 
ROI measurements. The diagnostic performance of the subgroup analysis and p-values 
of the above-mentioned factors and others are demonstrated in Table 3. 
 
Discussion 
This analysis indicates that high b-value imaging is a good diagnostic tool for detecting 
prostate cancer. The results of the threshold method subgroup analysis imply that there is 
a benefit in using higher bmax in a clinical setting. The lesser value of quantitative ADC 
thresholding as a tool for detecting tumor is in line with PI-RADS version 2 
recommendations (standardized reporting standards for prostate MRI) (32). The evidence 
on which this analysis was made was graded as ‘good’ quality using the QUADAS-2 tool. 
 
There have been multiple meta-analyses investigating the diagnostic accuracy of DWI 
alone or in combination with other imaging techniques (18–20). The pooled sensitivity, 
specificity, and overall accuracy of our study were 0.58, 0.92 and 0.92 respectively, 
similar to Jie et al’s (19) meta-analysis of DWI alone. This is likely due to overlap of 
included studies, with nine of the ten included studies featured in their meta-analysis. 
However, in contrast to Jin et al.’s meta-analysis of all b-values, the sensitivity was lower 
in our study (0.58 vs. 0.77), but the pooled specificity and AUC were higher (0.92 vs. 
0.84 and 0.92 vs. 0.88 respectively) (20). This suggests high b-value imaging may help 
to rule out  significant prostate cancer.  
 
There was significant statistical heterogeneity between the included studies that could not 
be explained by threshold effect. Subgroup analyses of multiple study parameters were 
assessed to attempt to explain the heterogeneity. Given the unknown cause of statistical 
heterogeneity, these findings should be interpreted cautiously.  
Improved tumor contrast at high b-values comes at the cost of decreased signal-to-noise 
(11); however, this can be mitigated through the use of 3T field strength. Most of the 
diagnostically specific high b-value diagnostic accuracy studies use 3T (12,33–35). The 
subgroup analysis of field strength demonstrated a trend towards improved accuracy with 
3T. The sensitivity results of the 3T group alone are similar and the specificity and 
accuracy are better than those found in a meta-analysis of accuracy of visual assessment 
of combined T2 and DWI sequences for prostate cancer detection by Wu et al. (21). 
 
On review of the method of prostate cancer detection, about half of the studies 
qualitatively assessed the ability of blinded readers to visually detect prostate cancer 
either by answering a binary question regarding cancer presence or using a probability 
scale (16,17,25,30). The remaining studies used ROI-based ADC calculations to 
determine prostate cancer presence or absence, or used a scale of ADC values to predict 
cancer (23,24,26–29). The diagnostic performance of tumor visual assessment on ADC 
maps was significantly better than quantitative ADC methods, with visual assessment 
giving similar results to Wu et al.’s combined T2 and DWI meta-analysis (18), indicating 
potential value for high b-value imaging clinically. 
A potential explanation for the relatively poor performance of quantitative ADC 
methods is four of the six studies included used biopsy as a reference standard whereas 
all visual assessment studies used radical prostatectomy specimens. TRUS biopsy as a 
reference standard is limited given its poor octant localization, small sampling volume, 
and substantial number of tumors missed (36,37). Radical prostatectomy studies 
performed better than biopsy studies, but the difference was not statistically significant.  
ADC estimation is influenced by a number of factors, including, but not limited to: 
noise, fat, and perfusion signals (8,38,39); possible non-Gaussian diffusion (7); and the 
known diffusion anisotropy of the prostate (40). Because of these confounds, other 
diffusion models may ultimately prove more appropriate for identifying prostate cancer 
(41,42) [R1 M3]. Along with the study-specific TE, diffusion gradient duration, δ, and 
diffusion time, Δ , such factors could substantially influence the sensitivity and 
specificity of DWI for evaluating prostate cancer. None of the studies reviewed reported 
δ and Δ;  Few researchers (42,43) have considered these factors when applying prostate 
DWI [R1 M1].  
 
None of the other subgroup analyses demonstrated a significant difference between the 
groups. In some subgroups a statistical difference would have been difficult to 
demonstrate given the small numbers of studies. For example, only three studies used 
biopsy as a reference standard, but despite this, this subgroup analysis provided the 
second strongest statistical source of heterogeneity (p=0.18). The limitations of biopsy as 
a reference standard are described above, but limiting MRI assessment to patients who 
have had a prostatectomy introduces patient selection bias, as radical prostatectomy 
patients tend to be younger,fitter, and tend to have clinically significant tumor, prompting 
surgery. Radical prostatectomy allows examination of the entire gland including the 
anterior gland (which TRUS cannot) and detects multifocality, which is frequent (44,45). 
Eight of nine studies in the prostatectomy subgroup assessed for multifocal disease or for 
tumor in multiple segments of the prostate and this subgroup’s results may be more 
representative of the diagnostic accuracy of high b-value diffusion. 
 
There are limitations to this study. Limitation  by language and database may have 
introduced bias. The use of two larger databases, and grey literature, should encompass 
most eligible English language studies.  Publication bias was not assessed as a Deek’s 
funnel plot is less accurate in meta-analyses with small numbers of studies (46). Finally, 
this study was restricted to testing localization of prostate cancer within the gland. This 
is important in determining the accuracy of high b-value diffusion, but not the only useful 
outcome. Identifying the presence of capsular breach, seminal vesicle invasion and pelvic 
lymphadenopathy are important staging and prognostic characteristics not assessed in this 
study. 
In conclusion, these findings should be considered cautiously given the degree of 
statistical heterogeneity. However, this meta-analysis demonstrated that high b-value 
diffusion is a valuable diagnostic tool, with a sensitivity of 59%, specificity of 92% and  
sROC AUC of 0.92.  There was better diagnostic performance by visual assessment of 
high b-value DWI studies compared to ADC quantification. 
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Table 1. Principle characteristics of included studies 
Study Year Country No. of 
patients 
Age (range) PSA (range) Design 
Chen 2008 China 42 63(45–82) 
52.5(4.7–
147) 
Retro 
Girometti 2012 Italy 26 64*(51–74) 6.0*(2.5–10) Pro 
Isebaert 2013 Belgium 75 66*(49–74) 
10.4(1.5–
70.9) 
Pro 
Kim 2000 
South 
Korea 
48 66(45–80) 
7.2*(2.3–
23.2) 
Retro 
Koo 2013 
South 
Korea 
80 66(45–81) 7.2(1.2–57) Retro 
Kumar 2007 India 23 64.5 
11*(0.5–
1000) 
Pro 
Lim 2009 
South 
Korea 
52 65(48–76) 66(45–80) Retro 
Peng 2013 USA 48 61.5(44–73) 
15.6(0.8–
256) 
Retro 
Rosenkrantz 2015 USA 58 63 8.2 Retro 
Vilanova 2011 Spain 70 63.5(43–87) 7.4*(4–17.2) Retro 
PSA – Prostate specific antigen (ng/mL), * Median, Pro – prospective, Retro – 
retrospective 
Table 2. Imaging and methodological characteristics of the included studies. 
 
Study Field 
Strength 
Coil b-values (s/mm2) TR/TE (ms) NSA Voxel Size (mm) RS Blind Spasm Threshold 
Used 
Chen 1.5T A 0 & 1000 3200/94 - 1.8 x 1.8 x - Bx Y U ADC  
Girometti 3T A 0, 800 & 1200 4600/60 6 2.3 × 2.5 × 3.0 Bx U Y ADC  
Isebaert 1.5T A 
0, 50, 100, 500, 750 
& 1000 
4000/79 - 3.0 × 3.0 × 4.0 RP Y U Visual 
Kim 3T A 0 & 1000; 0 & 2000 
2,740–2,950/ 
83–95 
3 1.8 × 1.8 × 3.0 RP Y Y Visual 
Koo 3T A 
0 & 300; 0 & 700; 0 
& 1000; 0 & 2000 
4830-4840/ 
75-76 
3 1.8 × 1.8 × 3.0 RP Y Y Visual Scale 
Kumar 1.5T B 
0, 250, 500, 750 & 
1000 
3000/96 - 
1.8 × 1.8 × 4.0–
5.0 
Bx Y U ADC   
Lim 3T A 0 & 1000 3400/117 - 0.9 × 0.9 × 4.0 RP Y Y Visual scale 
Peng 1.5T B 
0, 50, 200, 1500 & 
2000; 0 & 1000* 
2948–8616/ 
71–85 
1-4 
0.81 × 0.81-1.28 
× 1.28 
RP U Y ADC  
Rosenkrantz 3T A 50 & 1000 4100/86 10 2.0 × 0.9 × 3.0 RP Y U ADC  
Vilanova 1.5T B 0 & 1000 8250/94 6 2.0 × 2.0 × 3.0 C Y U ADC  
Coil A – without endorectal coil, Coil B – with endorectal coil, TR – repetition time, TE – Echo time, NSA – Number of signal averages, RS – 
reference standard, RP – radical prostatectomy, Bx – biopsy, C – both RP and Bx included,  Blind – Blinded, Y – yes, U – unclear, Spasm – 
Anti-spasmodics,  Th – Threshold, ADC – Apparent diffusion coefficient 
* 29 patients were imaged with b-values of 0,50, 200, 1500 and 2000; 24 patients were imaged with b-values of 0 and 1000. 
 
 
 
Table 3. Results of the subgroup analysis. 
 
 
 
  
Study 
characteristics 
No Pooled sensitivity  
(95% CI) 
Pooled specificity  
(95% CI) 
AUC p-value* 
Total 13 0.59 (0.57–0.91) 0.92 (0.91–0.92) 0.92  
b-value     0.31 
    1000 9 0.55 (0.53–0.58) 0.90 (0.89–0.92) 0.91  
     >1000 3 0.72 (0.67–0.76) 0.94 (0.93–0.95) 0.98  
Field strength     0.20 
     1.5T 6 0.49 (0.46–0.51) 0.90 (0.88–0.91) 0.89  
     3T 7 0.74 (0.71–0.79) 0.93 (0.92–0.94) 0.96  
Coil     0.32 
    With endorectal 4 0.76 (0.71–0.80) 0.86 (0.83–0.89) 0.84  
    Without endorectal 9 0.56 (0.53–0.58) 0.93 (0.92–0.93) 0.94  
Reference standard     0.16 
     Biopsy 3 0.73 (0.63–0.82) 0.86 (0.82–0.89) 0.86  
     Prostatectomy 9 0.56 (0.56–0.60) 0.92 (0.91–0.93) 0.94  
Threshold method     0.03 
    ADC 7 0.64 (0.59–0.69) 0.87 (0.84–0.89) 0.88  
    Visual 6 0.58 (0.55–0.60) 0.93 (0.92–0.93) 0.95  
Patient selection bias     0.29 
    High risk 10 0.58 (0.56–0.60) 0.92 (0.91–0.93) 0.94  
    Low risk 3 0.77 (0.68–0.84) 0.83 (0.79–0.87) 0.86  
AUC – Area under the curve. *p-value – comparison of diagnostic odds ratio of 
subgroups 
Figures 
 
Fig. 1. QUADAS-2 results summarizing the proportion of low, high and unclear risk of 
bias and applicability concerns.  
 
 
Fig. 2. Forest plot of sensitivity with pooled sensitivity, Q statistic of the chi-squared, 
and I-squared results. 
  
Fig. 3. Forest plot of specificity with pooled specificity, Q-statistic of the chi-squared, 
and I-squared results. 
 Fig. 4. The summary Receiver Operating Characteristic (sROC) curve for high b-value 
DWI in detecting prostate cancer. 
  
Supplementary Table 1. MEDLINE search strategy  
 
Search 
Number of 
studies 
1 "prostatic neoplasms/diagnosis"[MeSH Terms] 54849 
2 “diffusion magnetic resonance imaging” [MeSH Terms] 13053 
3 1 AND 2 402 
4 Limit 3 to Humans 398 
5 Limit 4 to English 372 
6 Limit 5 to Abstracts 351 
 
  
 Supplementary Table 2. Quality assessment of the included studies. 
 
 Risk of bias Applicability concerns 
Patient 
Selection 
Index 
test(s) 
Reference 
Test 
Flow & 
Timing 
Patient 
Selection 
Index 
test(s) 
Reference 
Test 
Chen + + - + + + + 
Girometti - + - - - + + 
Isebaert - + + U + + + 
Kim - + + + - + + 
Koo - + + + - + + 
Kumar + + - + + + + 
Lim - + + + + + + 
Peng - - + U - + + 
Rosenkrantz - + + U + + + 
Vilanova + + - +   +   +   + 
+ Low risk, – High risk, U Unclear risk 
 
  
Supplementary Table 3. Diagnostic performance of eligible studies and subsets. 
  
Study TP FP FN TN Sens Spec Notes 
Chen 42 37 9 164 0.82 0.82  
Girometti 4 14 8 182 0.33 0.93  
Isebaert 359 44 617 732 0.37 0.94  
Kim 158 49 22 443 0.88 0.92 b=1000 
 128 40 52 452 0.71 0.92 b=2000 
Koo 174 38 31 557 0.85 0.94 b=1000 
 152 22 53 573 0.74 0.96 b=2000 
Kumar 17 10 6 27 0.63 0.82  
Lim 171 57 56 340 0.75 0.86  
Peng 49 6 12 37 0.86 0.80  
Rosenkrantz 15 13 24 64 0.39 0.83 TZ 
 42 2 42 30 0.50 0.94 PZ 
Vilanova 37 8 14 81 0.73 0.91  
TP – true positives, FP – false positives, FN – false negatives, TN – true 
negatives, Sens – sensitivity, Spec – specificity, TZ – transitional zone, PZ – 
peripheral zone 
Supplementary Figure Legends 
 
Supplementary Fig. 1. Flow diagram for articles identified and included in this meta-
analysis. 
 
 
Supplementary Fig. 2. Forest plot of positive likelihood ratio with pooled positive 
likelihood ratio, Q statistic of the chi-squared, and I-squared results. 
 
 
Supplementary Fig. 3. Forest plot of negative likelihood ratio with pooled negative 
likelihood ratio, Q statistic of the chi-squared, and I-squared results. 
  
Supplementary Fig. 4. Sensitivity and 1-specificity plotted in Receiver Operating 
Characteristic curve for individual studies and subsets. 
 
